title: Multiple sclerosis treatment: First oral drug, new antibody therapies.
authors.affiliation: Department of Neurology and Neurotherapeutics, The Clinical Center for Multiple Sclerosis, University of Texas Southwestern Medical Center, Dallas, USA.
authors.forename: Teresa
authors.initials: T
authors.lastname: Frohman
authors.forename: Megan
authors.initials: M
authors.lastname: Orchard
authors.forename: Paula
authors.initials: P
authors.lastname: Hardeman
authors.forename: Daniel L
authors.initials: DL
authors.lastname: O'Donoghue
mesh_terms: D000284:Administration, Oral; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000627:therapeutic use*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine